X4 Pharmaceuticals (XFOR) News Today $0.51 +0.05 (+10.06%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)January 16, 2025 | markets.businessinsider.comX4 Pharmaceuticals' (XFOR) Buy Rating Reaffirmed at HC WainwrightJanuary 16, 2025 | americanbankingnews.comXFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine…January 15, 2025 | msn.comBuy Rating for X4 Pharmaceuticals Driven by Strategic Partnership and Strong ValuationJanuary 14, 2025 | markets.businessinsider.comX4 Pharmaceuticals (NASDAQ:XFOR) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Tuesday.January 14, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on X4 Pharmaceuticals (XFOR)January 14, 2025 | markets.businessinsider.comX4, Norgine enter exclusive licensing agreement for mavorixaforJanuary 13, 2025 | markets.businessinsider.comX4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New ZealandJanuary 13, 2025 | globenewswire.comFY2024 EPS Estimates for XFOR Reduced by AnalystJanuary 10, 2025 | americanbankingnews.comBrokers Set Expectations for XFOR FY2024 EarningsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at Brookline Capital Management cut their FY2024 EPS estimates for X4 Pharmaceuticals in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earningJanuary 9, 2025 | marketbeat.comUnusually active option classes on open December 10thDecember 11, 2024 | markets.businessinsider.comX4 Pharmaceuticals to present on Phase 3 study of MavorixaforDecember 5, 2024 | markets.businessinsider.comX4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & ExpositionDecember 4, 2024 | markets.businessinsider.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comB. Riley Expects Stronger Earnings for X4 PharmaceuticalsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at B. Riley raised their FY2024 earnings per share (EPS) estimates for X4 Pharmaceuticals in a research note issued to investors on Monday, November 18th. B. Riley analyst K. Patel now expects that the company willNovember 20, 2024 | marketbeat.comResearch Analysts Set Expectations for XFOR FY2024 EarningsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of X4 Pharmaceuticals in a research note issued on Thursday, November 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will eNovember 18, 2024 | marketbeat.comX4 Pharmaceuticals price target lowered to $1.50 from $5 at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comXFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…November 14, 2024 | msn.comX4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...November 14, 2024 | finance.yahoo.comX4 Pharmaceuticals Reports Positive Trial Results and ProgressNovember 14, 2024 | markets.businessinsider.comX4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare ConferenceNovember 14, 2024 | globenewswire.comX4 Pharmaceuticals price target lowered to $4 from $5 at StifelNovember 14, 2024 | markets.businessinsider.comX4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comX4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | markets.businessinsider.comX4 Pharmaceuticals Posts Wider Loss In Q3 - Quick FactsNovember 13, 2024 | markets.businessinsider.comX4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comX4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)November 13, 2024 | globenewswire.comX4 Pharmaceuticals (XFOR) to Release Earnings on WednesdayX4 Pharmaceuticals (NASDAQ:XFOR) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639867)November 6, 2024 | marketbeat.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comX4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024October 24, 2024 | globenewswire.comInsider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells 31,897 Shares of StockOctober 17, 2024 | insidertrades.comPaula Ragan Sells 31,897 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) StockX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) CEO Paula Ragan sold 31,897 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $0.56, for a total value of $17,862.32. Following the completion of the sale, the chief executive officer now directly owns 1,025,816 shares in the company, valued at $574,456.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.October 16, 2024 | marketbeat.comActelis Networks Announces Follow-On Order from U.S. Department of Transportation Agency Expanding Footprint to New RegionsOctober 15, 2024 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells $38,586.15 in StockOctober 9, 2024 | insidertrades.comActelis Receives Expansion Order for Major Italian National Transportation Infrastructure ProjectOctober 2, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | globenewswire.comActelis Networks Receives $200,000 Order to Provide Fast Upgrade and Modernization to US Army National Guard Base NetworkSeptember 26, 2024 | globenewswire.comGV 2016 GP, L.L.C.'s Net WorthSeptember 19, 2024 | benzinga.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a favorite amongst institutional investors who own 51%September 18, 2024 | finance.yahoo.comActelis Receives New Significant Order for Major U.S. Department of Aerial Transportation AgencySeptember 9, 2024 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 1.3% X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Down 1.3%September 6, 2024 | marketbeat.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | globenewswire.comActelis Networks to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comX4 Pharmaceuticals to Participate in Upcoming September Investor ConferencesAugust 28, 2024 | globenewswire.comActelis Receives New Order for Intelligent Traffic System (ITS) Networking in New York City Metro AreaAugust 27, 2024 | globenewswire.comActelis Announces Strategic Partnership to Launch AI-Powered Cybersecurity SaaS for IoT NetworksAugust 19, 2024 | globenewswire.comActelis Networks Reports Q2 2024 Results: 372% Sequential Revenue Growth, 81% Year-Over-Year Increase, and Positive EBITDAAugust 14, 2024 | globenewswire.comXFOR: First Commercial Sales of XOLREMDI™…August 13, 2024 | msn.comHC Wainwright Comments on X4 Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:XFOR)X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at HC Wainwright increased their FY2028 EPS estimates for X4 Pharmaceuticals in a research note issued to investors on Friday, August 9th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.3August 12, 2024 | marketbeat.com Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address XFOR Media Mentions By Week XFOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XFOR News Sentiment▼0.280.44▲Average Medical News Sentiment XFOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XFOR Articles This Week▼73▲XFOR Articles Average Week Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NMRA News Today MBX News Today PGEN News Today OLMA News Today CRVS News Today CTNM News Today CMRX News Today LFVN News Today ENGN News Today TSHA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XFOR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
